Senores Pharmaceuticals, Inc. Announces Strategic Joint Venture to Target U.S. Federal and Defense Sector Supplies
Atlanta, USA / Ahmedabad, India, April 03, 2026 – Senores Pharmaceuticals, Inc. ('SPI'), a wholly owned subsidiary of Senores Pharmaceuticals Limited, announced a strategic partnership through the execution of a formal Operating Agreement on April 2, 2026. This agreement has led to the formation of a Joint Venture ('JV') entity, Amerisyn, LLC ('Amerisyn').The partnership positions Senores to supply its product portfolio to the U.S. Federal Government, veterans affairs, and military supply contracts.
“Amerisyn is a major milestone for Senores," stated Swapnil Shah, Managing Director, Senores Pharmaceuticals Limited. "This will enable Senores to utilize its manufacturing and product expertise for supply to the U.S. government sector and unlock a high-entry-barrier market. We expect this partnership to be a significant driver of growth and a substantial contributor to our international business volumes moving forward.”
Senores Pharmaceuticals Limited is a global, research-driven pharmaceutical company developing and manufacturing a wide range of pharmaceutical products for the US, Canada, and other markets. The company's portfolio includes 46 ANDAs and 137 strengths, with a pipeline of 22 ANDAs and 52 strengths. They also have 16 ANDAs and 34 products permitted for distribution in the USA, along with a pipeline of 16 ANDAs and 35 strengths in the CMO/CDMO vertical.
Senores currently has approval from regulatory bodies of more than 10 countries for its manufacturing facility in Chhatral for emerging markets, with over 450 product registrations and 858 product applications. The company manufactures critical care injectables and Active Pharmaceutical Ingredients ('API').
Senores has three manufacturing facilities for formulations: one in Atlanta, US, which is USFDA approved and DEA, TAA & BAA compliant; a second in Baroda, approved by USFDA, Health Canada, and UKMHRA; and a third in Chhatral, Ahmedabad, India, approved by WHO-GMP. They also have two API manufacturing facilities in India, both located around Ahmedabad. Senores has research and development capabilities across three sites, including locations in the USA and India.
Source:
Disclaimer: Due care and diligence have been taken in compiling and presenting news and market-related content. However, errors or omissions may arise despite such efforts.
The information provided is for general informational purposes only and does not constitute investment advice, a recommendation, or an offer to buy or sell any securities. Readers are advised to rely on their own assessment and judgment and consult appropriate financial advisers, if required, before taking any investment-related decisions.